- Home
- BLKB vs INBX Comparison
BLKB vs INBX Comparison
Compare BLKB & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLKB | INBX |
|---|---|---|
| Founded | 1981 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2004 | 2024 |
Fundamental Metrics
Financial Performance| Metric | BLKB | INBX |
|---|---|---|
| Price | $47.20 | $126.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $50.00 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 579.0K | 228.4K |
| Earning Date | 04-29-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.32 | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $6.26 | N/A |
| Revenue Next Year | $4.25 | N/A |
| P/E Ratio | $32.25 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $25.58 | $26.19 |
| 52 Week High | $70.71 | $155.29 |
Technical Indicators
Market Signals| Indicator | BLKB | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 68.72 | 76.64 |
| Support Level | $45.83 | $72.39 |
| Resistance Level | $50.76 | $153.14 |
| Average True Range (ATR) | 1.82 | 8.17 |
| MACD | -0.25 | 3.89 |
| Stochastic Oscillator | 89.16 | 87.79 |
Price Performance
Historical ComparisonAbout BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.